Geometry Dash APK Hill Climb Racing APK
71.3 F
New York
Tuesday, October 3, 2023

Seres Therapeutics Inc. (NASDAQ:MCRB) Stock is Plummeting, Here is Why

Must read

Seres Therapeutics Inc. (MCRB) shares are trading at lower $27.61 and the avg recommendation for the stock is Strong Buy, while the current analyst price target stands at $37.50.

To add more color to this target, the company’s high over the last year is $38.50 and the low is $2.52. Over the last 52 weeks, MCRB is up 598.99% while the S&P 500 is up 15.19%. The catalyst for this interesting swing was the company’s recent earnings report.

A Notable Earnings Report

In the last quarter, MCRB reported a profit of $31.41 million. Seres Therapeutics Inc. also saw revenues increase to $1.42 million. In addition, MCRB has free cash flow of -$76.05 million as of 09-2020. The company’s EBITDA came in at -$28.09 million which compares well with its peers.

MCRB Return on Assets is -51.20%. All told, it is clear that, MCRB needs to be on your watchlist.

Find out when MCRB reaches critical levels. Subscribe to Right Now by entering your Email in the box below.

Of course, we must look beyond the financials and question how well those numbers represent the sustainable earnings power of the business. Investors need to know how sustainable this current run. MCRB has a short ratio of 7.03 and outstanding shares of 83.53M.

Company Outlook

MCRB has seen increased volume after this news and investors are putting their support behind the value proposition. Furthermore, 10-day volume stands at 0.91 million and more growth is possible in the weeks ahead. Traders will also note the company’s earnings per share came in at -1.19. Seres Therapeutics Inc. MCRB also noted assets of $356.2 million at the end of the last quarter. Investors should also keep an eye on sector updates as MCRB has historically followed its peers on positive news.

All told, Seres Therapeutics Inc. MCRB has strung together solid data and demonstrated underlying fundamentals. At its current valuation, MCRB represents an interesting risk/reward case. Traders should stay tuned to see if this recent report will push the stock to test recent resistance levels.

Seres Therapeutics Inc. MCRB is now commanding a market cap of 2.55B and a float of 83.16M. MCRB is increasing its credibility in this sector and that could lead to more upside down the line. Sign-up for continuing coverage on shares of MCRB stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in MCRB, either long or short, and we have not been compensated for this article.

Latest article